AC
SCPH

Armistice Capital’s scPharmaceuticals SCPH Stock Holding History

Armistice Capital’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,148,000
Closed -$15.4M – 249
2022
Q4 		$15.4M Sell
2,148,000
-344,000
-14% -$2.1M 0.27% 62
2022
Q3 		$16.2M Sell
2,492,000
-208,000
-8% -$1.11M 0.28% 65
2022
Q2 		$13M Buy
+2,700,000
New +$13.4M 0.23% 74

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

Armistice Capital's SCPH Position: Q1 2023 in Review

Armistice Capital sold out of scPharmaceuticals (SCPH) in Q1 2023, closing a stake of 2,148,000 shares — an estimated $15.4M sold.

Armistice Capital first reported a position in SCPH in Q2 2022 and held it in 3 quarters. The position peaked at $16.2M in Q3 2022. 62 funds tracked by Wall St. Rank hold SCPH as of Q1 2023.

  • Armistice Capital reported no remaining scPharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Armistice Capital sold 2,148,000 scPharmaceuticals shares in Q1 2023, an estimated $15.4M.
  • Armistice Capital first reported a position in scPharmaceuticals in Q2 2022 and held it in 3 quarters.
  • Armistice Capital's scPharmaceuticals position peaked at $16.2M in Q3 2022.
  • 62 funds tracked by Wall St. Rank held scPharmaceuticals as of Q1 2023.

Based on Armistice Capital's 13F filing for Q1 2023, filed 15 May 2023.